FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1897-1908 October 30, 2008 Number 18 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Schunkert, H. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

ABSTRACT

Background Elevated levels of C-reactive protein (CRP) are associated with increased risks of ischemic heart disease and ischemic cerebrovascular disease. We tested whether this is a causal association.

Methods We studied 10,276 persons from a general population cohort, including 1786 in whom ischemic heart disease developed and 741 in whom ischemic cerebrovascular disease developed. We examined another 31,992 persons from a cross-sectional general population study, of whom 2521 had ischemic heart disease and 1483 had ischemic cerebrovascular disease. Finally, we compared 2238 patients with ischemic heart disease with 4474 control subjects and 612 patients with ischemic cerebrovascular disease with 1224 control subjects. We measured levels of high-sensitivity CRP and conducted genotyping for four CRP polymorphisms and two apolipoprotein E polymorphisms.

Results The risk of ischemic heart disease and ischemic cerebrovascular disease was increased by a factor of 1.6 and 1.3, respectively, in persons who had CRP levels above 3 mg per liter, as compared with persons who had CRP levels below 1 mg per liter. Genotype combinations of the four CRP polymorphisms were associated with an increase in CRP levels of up to 64%, resulting in a theoretically predicted increased risk of up to 32% for ischemic heart disease and up to 25% for ischemic cerebrovascular disease. However, these genotype combinations were not associated with an increased risk of ischemic vascular disease. In contrast, apolipoprotein E genotypes were associated with both elevated cholesterol levels and an increased risk of ischemic heart disease.

Conclusions Polymorphisms in the CRP gene are associated with marked increases in CRP levels and thus with a theoretically predicted increase in the risk of ischemic vascular disease. However, these polymorphisms are not in themselves associated with an increased risk of ischemic vascular disease.

Source Information

From the Department of Clinical Biochemistry (J.Z., B.G.N.) and the Copenhagen General Population Study (J.Z., A.T.-H., J.S.J., B.G.N.), Herlev Hospital; the Departments of Clinical Biochemistry (A.T.-H.), Cardiology (P.G.), and Vascular Surgery (H.S.), Rigshospitalet; the Copenhagen City Heart Study, Bispebjerg Hospital (A.T.-H., J.S.J., B.G.N.); and the Department of Cardiology, Gentofte Hospital (J.S.J.) — all at Copenhagen University Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen.

Address reprint requests to Dr. Nordestgaard at the Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark, or at brno{at}heh.regionh.dk.

Full Text of this Article

Related Letters:

Genetically Elevated C-Reactive Protein and Vascular Disease
Harbord R. M., Lawlor D. A., Smith G. D., Bubb M. R., Morita H., Nagai R., Zacho J., Tybjærg-Hansen A., Nordestgaard B. G.
Extract | Full Text | PDF  
N Engl J Med 2009; 360:933-935, Feb 26, 2009. Correspondence

This article has been cited by other articles:

• Jaleel, A., Klaus, K. A., Morse, D. M., Karakelides, H., Ward, L. E., Irving, B. A., Nair, K. S. (2009). Differential effects of insulin deprivation and systemic insulin treatment on plasma protein synthesis in type 1 diabetic people. Am. J. Physiol. Endocrinol. Metab. 297: E889-E897 [Abstract] [Full Text]  
• MELICHAR, B., KALABOVA, H., KRCMOVA, L., URBANEK, L., HYSPLER, R., SOLICHOVA, D., MELICHAROVA, K., PECKA, M., ZADAK, Z. (2009). Effect of Aromatase Inhibitors on Lipid Metabolism, Inflammatory Response and Antioxidant Balance in Patients with Breast Carcinoma. Anticancer Res 29: 3337-3346 [Abstract] [Full Text]  
• Elliott, P., Chambers, J. C., Zhang, W., Clarke, R., Hopewell, J. C., Peden, J. F., Erdmann, J., Braund, P., Engert, J. C., Bennett, D., Coin, L., Ashby, D., Tzoulaki, I., Brown, I. J., Mt-Isa, S., McCarthy, M. I., Peltonen, L., Freimer, N. B., Farrall, M., Ruokonen, A., Hamsten, A., Lim, N., Froguel, P., Waterworth, D. M., Vollenweider, P., Waeber, G., Jarvelin, M.-R., Mooser, V., Scott, J., Hall, A. S., Schunkert, H., Anand, S. S., Collins, R., Samani, N. J., Watkins, H., Kooner, J. S. (2009). Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease. JAMA 302: 37-48 [Abstract] [Full Text]  
• Shah, S. H., de Lemos, J. A. (2009). Biomarkers and Cardiovascular Disease: Determining Causality and Quantifying Contribution to Risk Assessment. JAMA 302: 92-93 [Full Text]  
• Wheeler, D. C. (2009). The Jupiter trial--new territory for statins?. Nephrol Dial Transplant 24: 2036-2037 [Full Text]  
• Abedini, S., Holme, I., Marz, W., Weihrauch, G., Fellstrom, B., Jardine, A., Cole, E., Maes, B., Neumayer, H.-H., Gronhagen-Riska, C., Ambuhl, P., Holdaas, H., on behalf of the ALERT study group, (2009). Inflammation in Renal Transplantation. CJASN 4: 1246-1254 [Abstract] [Full Text]  
• Thanassoulis, G., O'Donnell, C. J. (2009). Mendelian Randomization: Nature's Randomized Trial in the Post-Genome Era. JAMA 301: 2386-2388 [Full Text]  
• Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., Iskandrian, A. E. (2009). The scope of coronary heart disease in patients with chronic kidney disease.. J Am Coll Cardiol 53: 2129-2140 [Abstract] [Full Text]  
• Sanz, J., Moreno, P. R., Fuster, V. (2009). The year in atherothrombosis.. J Am Coll Cardiol 53: 1326-1337 [Full Text]  
• Sattar, N., Hingorani, A. D. (2009). C-Reactive Protein and Prognosis in Diabetes: Getting to the Heart of the Matter. Diabetes 58: 798-799 [Full Text]  
• Plump, A. S., Lum, P. Y. (2009). Genomics and cardiovascular drug development.. J Am Coll Cardiol 53: 1089-1100 [Abstract] [Full Text]  
• Harbord, R. M., Lawlor, D. A., Smith, G. D., Bubb, M. R., Morita, H., Nagai, R., Zacho, J., Tybjaerg-Hansen, A., Nordestgaard, B. G. (2009). Genetically Elevated C-Reactive Protein and Vascular Disease. NEJM 360: 933-935 [Full Text]  
• Ridker, P. M (2009). C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease. Clin. Chem. 55: 209-215 [Full Text]  
• Hingorani, A. D., Shah, T., Casas, J. P., Humphries, S. E., Talmud, P. J. (2009). C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target?. Clin. Chem. 55: 239-255 [Abstract] [Full Text]  
• Vasan, R. S (2009). Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness. Int J Epidemiol 38: 231-234 [Full Text]  
• SHISHEHBOR, M. H., HAZEN, S. L. (2009). JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. Cleveland Clinic Journal of Medicine 76: 37-44 [Abstract] [Full Text]  
• (2008). All you need to read in the other general journals. BMJ 337: a2391-a2391 [Full Text]  
• Schunkert, H., Samani, N. J. (2008). Elevated C-Reactive Protein in Atherosclerosis -- Chicken or Egg?. NEJM 359: 1953-1955 [Full Text]  
• (2008). C-Reactive Protein and Atherosclerosis: No Case for Causality. Journal Watch Cardiology 2008: 1-1 [Full Text]